PASTIC Dspace Repository

Effects of a combination of erythromycin sequential therapy and azithromycin on lung function and inflammatory factors in children with severe mycoplasma pneumonia

Show simple item record

dc.contributor.author Wang, Fang
dc.contributor.author Nan, Kai
dc.contributor.author Hao, Lingfeng
dc.contributor.author Li, Haitao
dc.contributor.author Wang, Congmin
dc.contributor.author Zhang, Lina
dc.contributor.author Jiang, Lili
dc.contributor.author Tian, Yunxiao
dc.date.accessioned 2022-10-28T07:56:31Z
dc.date.available 2022-10-28T07:56:31Z
dc.date.issued 2021-11-10
dc.identifier.citation Wang, F., Nan, K., Hao, L., Li, H., Wang, C., Zhang, L., ... & Tian, Y. (2021). Effects of a combination of erythromycin sequential therapy and azithromycin on lung function and inflammatory factors in children with severe mycoplasma pneumonia. Pakistan Journal of Pharmaceutical Sciences, 34(6 (Special)), 2447-2454. en_US
dc.identifier.issn 1011-601X
dc.identifier.uri http://142.54.178.187:9060/xmlui/handle/123456789/13841
dc.description.abstract This study aimed to investigate the effect of erythromycin sequential therapy plus azithromycin on lung function and inflammatory factors in children with severe mycoplasma pneumonia (MP). Ninety-three severe MP children were selected and randomized into azithromycin group, erythromycin group, and combination group, 31 cases in each. The disappearance time of cough, fever, lung rale and X-ray shadow in the combination group were shorter than those in the azithromycin group and erythromycin group. The clinical treatment efficiency of the combination group was higher than that of the azithromycin group. After treatment, FVC, FEV1/FVC and PEF in combination group were higher than before treatment; IL-8, IL-6, CRP in combination group were lower than erythromycin group and azithromycin group. IL-8, IL-6, CRP are negatively correlated with disappearance time of cough, fever, pulmonary rale, X-ray shadow and clinical treatment efficiency; FEV1/FVC is positively correlated with disappearance time of cough and fever, pulmonary rales and X-ray shadow, and clinical treatment efficiency. Sequential erythromycin therapy combined with azithromycin in the treatment of MP can effectively inhibit high inflammatory reactions, control the disease in a timely manner, improve lung function and produce fewer adverse reactions. en_US
dc.language.iso en en_US
dc.publisher Karachi:Pakistan Journal of Pharmaceutical Sciences, university of Karachi. en_US
dc.subject Erythromycin sequential therapy en_US
dc.subject azithromycin en_US
dc.subject severe mycoplasma pneumonia en_US
dc.subject lung function en_US
dc.subject inflammatory factors en_US
dc.title Effects of a combination of erythromycin sequential therapy and azithromycin on lung function and inflammatory factors in children with severe mycoplasma pneumonia en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account